Intertek Melbourn

Intertek Melbourn provides GMP pharmaceutical analysis and formulation contract services for the pharmaceutical, biopharmaceutical and drug delivery industries with specialist expertise in inhalation development and other dosage forms
Intertek Melbourn has provided GMP pharmaceutical analytical testing and formulation development services to the global pharmaceutical industry for nearly 30 years.
Our team of scientists have a reputation for providing outstanding and responsive customer service from our Melbourn Scientific Ltd laboratory, located near Cambridge, UK, which was acquired by Intertek in 2013. Intertek Melbourn opened a second facility in 2015 following increased client demand for stability storage. In 2019 a further expansion was announced which would double the laboratory footprint at the present location.
Intertek Melbourn has specialist skills and experience in analytical testing and formulation for both small molecule and biologic orally inhaled and nasal drug products (OINDP), alongside all other pharmaceutical dosage forms. Clients include major pharmaceutical companies, drug delivery innovators, consultants and virtual companies. Intertek Melbourn has invested continually in the latest equipment and provides a range of services; pre-formulation and formulation, analytical support, method development and validation; stability studies, stability storage, GMP batch release testing and clinical trial materials manufacturing.
Our Intertek Centre of Excellence for Inhaled Biologics deploys a strategic programme of orthogonal analytical methods which aim to both fully characterise the biological entity and establish whether the device delivery mechanism (e.g. actuation through an inhaler) has adversely affected parameters. We have combined our 30 years of experience in biologics characterisation, from small peptides up to monoclonal antibodies and conjugated species, and contract testing, formulation and clinical manufacturing services for inhaled and nasal drug products to help you overcome the complexity in developing biologic drugs for delivery via the lungs and the nose.
The laboratory is inspected and approved by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for GMP compliance. The Laboratory has also been inspected by the US Food and Drug Administration (FDA) against GMP as part of clients’ pre-approval inspections.
Pharmaceutical Services:
- Pharmaceutical Analytical Services
- Pre-formulation and Formulation Development
- Inhaled Product Development
- Inhaled Product Analysis
- Inhaled and Nasal Biologic Drug Development and Testing
- Nasal Drug Product Testing and Development
- Analytical Method Development and Validation
- cGMP Stability Studies
- Pharmaceutical Powder and Particle Morphology
- Chemistry, Manufacturing and Controls (CMC) Support
- Clinical Trial GMP Manufacture
- QC Testing
- GMP Batch Release Testing
- Dissolution Testing
- Pharmaceutical Shared Audits
ON DEMAND WEBINARS
Repurposing Products for Inhaled Delivery - Rapid Response Strategies
Advanced Analytical Techniques for Testing OINDP
Formulation and Manufacturing Approaches for Nasal Drug Products
Formulation Strategies for Orally Inhaled and Nasal Drug Products
ARTICLE DOWNLOADS
Repurposing Vaccines for Intranasal Development
In Vitro Bioequivalence for Pulmonary and Nasal Delivery
Nebulised Drug Development Considerations
Overcoming Challenges to Inhaled Biologic Development
Assessment of Foreign Particulate Matter in DPI Formulations
Introduction to Inhalation Drug Stability Studies
Intertek Melbourn
GMP analytical and formulation services to the pharmaceutical, biotech and healthcare industries
Intertek Melbourn
Saxon Way, Melbourn
Herts, SG8 6DN
UK
Recent News:
Intertek expands facility as global demand increases for specialist OINDP development for biologics
WHITE PAPER: Best Practice for Pharma Remote Audits
ARTICLE: Biomarker Development & Validation
WHITE PAPER: Strategic Partnerships with Contract Laboratory Organisations
WHITE PAPER: Mitigating Risks in Pharmaceutical Batch Release
WEBINAR: A Hi-Res Accurate Mass Spectrometry Validated Method for Nitrosamine Analysis
WEBINAR: Optimising Protein Impurity Analysis for AAV Capsids
REPORT:Peptide Therapeutics, Designing a Strategic QC Program
ARTICLE:Biophysical Characterisation of Biosimilars
WEBINAR: Glycosylation Site Specific Approaches for Antibody Therapies
WEBINAR: QC Strategy for Vaccine Development
eBOOK: Contingency Outsourcing Solutions
Access our comprehensive Digital Resource Library